Holocene Advisors Invests $163.96M in DexCom

The hedge fund buys a major stake in the medical device company.

Mar. 16, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Holocene Advisors LP, a hedge fund, has purchased a new $163.96 million stake in DexCom, Inc. (NASDAQ:DXCM), a medical device company that develops continuous glucose monitoring (CGM) systems for people with diabetes. The fund bought 2,436,672 shares of DexCom's stock, giving it a 0.62% ownership stake in the company.

Why it matters

This investment by Holocene Advisors, a prominent hedge fund, signals confidence in DexCom's growth potential in the CGM market. DexCom's products help diabetes patients better manage their condition, which is an increasingly important area of healthcare as the disease becomes more prevalent.

The details

According to a 13F filing with the SEC, Holocene Advisors purchased the DexCom shares during the third quarter of the year. The fund's investment represents a significant new position, as it did not previously own any DexCom stock. The purchase makes Holocene one of DexCom's larger institutional investors.

  • Holocene Advisors bought the DexCom shares during the third quarter of 2026.

The players

Holocene Advisors LP

A hedge fund that has purchased a new $163.96 million stake in medical device company DexCom, Inc.

DexCom, Inc.

A medical device company that develops continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

Holocene Advisors' substantial investment in DexCom reflects the hedge fund's belief in the company's potential to capitalize on the growing demand for advanced diabetes management technologies. This move underscores DexCom's position as a leader in the continuous glucose monitoring market.